QED Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.qedtx.com
Prospective Clinical Assessment Study in Children with Hypochondroplasia
- Conditions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06410976
- Locations
- 🇺🇸
Childrens Hospital Colorado, Aurora, Colorado, United States
🇺🇸Children's National Hospital, Washington DC, District of Columbia, United States
🇺🇸Johns Hopkins School of Medicine, Baltimore, Maryland, United States
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
- Conditions
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06164951
- Locations
- 🇬🇧
QED Investigative Site, Sheffield, United Kingdom
Extension Study of Infigratinib in Children with Achondroplasia (ACH)
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT05145010
- Locations
- 🇬🇧
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
🇺🇸USCF Benioff Children's Hospital, Oakland, Oakland, California, United States
🇺🇸Nemours Alfred I. Dupont Hospital for Children, Wilmington, Delaware, United States
Study of Infigratinib in Children with Achondroplasia
- Conditions
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04265651
- Locations
- 🇺🇸
Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸UCSF Benioff Children's Hospital, Oakland, California, United States
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04197986
- Locations
- 🇺🇸
The Ohio State University College of Medicine, Columbus, Ohio, United States
🇺🇸Associated Medical Professionals - Syracuse, Syracuse, New York, United States
🇺🇸New Jersey Urology - Saddle Brook, Saddle Brook, New Jersey, United States
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
- Conditions
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04035811
- Locations
- 🇺🇸
Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸Nemours Alfred I. Dupont Hospital for Children, Wilmington, Delaware, United States
🇦🇷Hospital de PediatrÃa SAMIC Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
- Conditions
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03773302
- Locations
- 🇺🇸
Parkland Health and Hospital System, Dallas, Texas, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT02150967
- Locations
- 🇬🇧
QED Investigative Site, Nottingham, United Kingdom